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Abstract
Background:  IQGAP1 is a scaffolding protein and overexpressed in many human tumors,
including ovarian cancer. However, the contribution of IQGAP1 to invasive properties of ovarian
cancer cells remains unknown. Here, we investigated the effect of IQGAP1-specific short hairpin
RNA (shRNA) expressing plasmids on metastatic potential of ovarian cancer HO-8910PM cells.
Methods: We used RT-PCR and Western blot analysis to characterize expression of IQGAP1 in
three human ovarian cancer-derived cell lines SK-OV-3, HO-8910 and HO-8910PM. We then
determined whether expression of endogenous IQGAP1 correlated with invasive and migratory
ability by using an in vitro Matrigel assay and cell migration assay. We further knocked down
IQGAP1 using shRNA expressing plasmids controlled by U1 promoter in HO-8910PM cells and
examined the proliferation activity, invasive and migration potential of IQGAP1 shRNA
transfectants using MTT assay, in vitro Matrigel-coated invasion assay and migration assay.
Results: IQGAP1 expression level seemed to be closely associated with the enhanced invasion and
migration in ovarian cancer cell lines. Levels of both IQGAP1 mRNA and protein were significantly
reduced in HO-8910PM cells transfected with plasmid-based IQGAP1-specific shRNAs. RNAi-
mediated knockdown of IQGAP1 expression in HO-8910PM cells resulted in a significant decrease
in cell invasion and migration.
Conclusion: Our findings support the hypothesis that IQGAP1 promotes tumor progression and
identify IQGAP1 as a potential therapeutic strategy for ovarian cancer and some other tumors with
over-expression of the IQGAP1 gene.
Background
Ovarian carcinomas are high aggressive tumors associated
with high mortality and morbidity in gynecology [1]. The
poor prognosis of the patients with advanced stage ovar-
ian cancerovarian cancer is largely attributed to the
advanced stage of disease at the time of diagnosis. Despite
the therapeutic advance, the 5-year survival rate for
patients with advanced stage ovarian cancer still remains
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at 15–30% [2]. These poor outcomes are due mainly to
the progression and metastasis of the disease after the
standard surgical treatment. Clearly, a better understand-
ing of the molecular mechanisms underlying the progres-
sion of ovarian carcinomas is needed to control the
disease.
IQGAP1 is a scaffolding protein and binds to a diverse
array of signaling and structural molecules, such as F-actin
[3], calmodulin [4], CLIP-170 [5], E-cadherin [6] and
small GTPases (Cdc42 and Rac1) [7]. Previous studies
have shown that IQGAP1 expression is up-regulated in
human colorectal carcinoma, especially in invasion front
[8]. In addition, IQGAP1 has been suggested to regulate
Salmonella invasion through interactions with actin,
Rac1, and Cdc42 [9]. We have also reported that IQGAP1
was overexpressed in ovarian adenocarcinomas compared
with adenomas and borderline tumors and its expression
significantly correlated with poor prognosis in patients
with ovarian carcinomas [10]. These lines of evidence
have suggested the functional linkage between IQGAP1
and ovarian cancer invasion. However, the exact mecha-
nisms by which IQGAP1 regulates invasion and metasta-
sis of ovarian carcinomas have not yet been elucidated.
RNA interference (RNAi) was a recently discovered antivi-
ral mechanism in plants and invertebrates induced by
small double-stranded RNA (dsRNA), which will lead to
sequence-specific gene silencing at the post-transcrip-
tional level [11]. Short hairpin RNAs (shRNAs) driven by
polymerase III promoters have been investigated as an
alternative strategy to suppress gene expression more sta-
bly, and such constructs with well-defined initiation and
termination sites have been used to produce various small
dsRNA species that inhibit the expression of genes with
diverse functions in mammalian cell lines [12].
In this study, we examined the effects of IQGAP1 silencing
on cell invasion and migration, and explored it as a ther-
apeutic target for metastasis of human ovarian carcinoma
cells. We showed that a significant reduction in IQGAP1
expression can markedly inhibit the invasion and migra-
tion potentials of ovarian cancer HO-8910PM cells. Thus,
our results provide new evidence of the potential use of
IQGAP1-targeted RNAi as a novel way to reduce tumor
progression of patients with ovarian cancer.
Methods
Cell culture
The human ovarian cancer cell line SK-OV-3, HO-8910 (a
human ovarian cancer cell line established from a patient
with poorly-differentiated serous carcinoma) and HO-
8910PM (a highly metastatic cell line derived from HO-
8910) [13] were grown in RPMI 1640 medium (Gibco)
supplemented with 10% of fetal bovine serum (Cambrex
Bio Science, Walkersville, MD). The cells were maintained
at 37°C in a humidified atmosphere of 5% CO2.
IQGAP1 silencing
shRNA plasmids (KH0073P) that specifically knock out
human IQGAP1 (NM_003870) were obtained from Bio-
science Corporation. The oligonucleotide sequence was as
follows: 5'-CAACGACATTGCCAGGGATAT-3' (Clone 1),
5'-AAACTGACCCTGTGGATATTT-3' (Clone 2), 5'-ACA-
GATTCCTGCAGCTAAACT-3' (Clone 3), 5'-GCATGCT-
GCAGCTAAACT-3' (Clone 4) and 5'-GGAATCTCATTCGA
TGCATAC-3' (scrambled control). HO-8910PM cells at
80% confluency were transfected with Lipofectamine
PLUS Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer's instructions. For establishing stable
clones, the transfected cells were selected in RPMI 1640
medium containing puromycin (Sigma, USA) at 1 μg/ml
48 h post-transfection. Selected clones of HO-8910PM
cells were expanded into clone 1-, clone 2-, clone 3-, clone
4-HO-8910PM-shIQGAP1 cells and scrambled control-
transfectants (HO-8910PM-shRNA negative), respec-
tively.
MTT assay
For measurements of cell proliferation rates, 1 × 103 cells/
100  μl medium were plated into each well of 96-well
plates. After 24, 48, 72 or 96 h incubation, 10 μl of MTT
solution (Cell counting kit-8, Dojindo, Kumamoto,
Japan) was added into each well, and plates were incu-
bated for 4 h at 37°C, and 450 nm UV absorbance of each
sample was measured in a microplate reader. Assay was
done in triplicate wells, and each experiment was repeated
three times.
In vitro Matrigel invasion assay
Matrigel invasion assay was performed using a 24-well
invasion chamber system (BD Biosciences, Bedford, MA)
with Matrigel membrane (8.0-μm pore), as described in
our previous report [14]. Briefly, each 750 μl of RPMI
1640 medium supplemented with 20% FBS and 10 μg/ml
of bovine fibronectin (chemoattractant) was placed in the
lower compartment of the chamber. In the prewarmed
and rehydrated upper compartment, 2 × 104 cells in 500
μl of RPMI 1640 medium supplemented with 20% FBS
were added, and the cells were allowed to migrate through
the intermediate membrane for 24 h at 37°C. Membranes
were then fixed with 10% neutral-buffered formalin and
stained in 5% Giemsa solution. The cells attached to the
lower side of the membrane were counted in 10 high-
powered (×200) fields under a microscope. Assays were
done in triplicate for each experiment, and each experi-
ment was repeated three times.Journal of Experimental & Clinical Cancer Research 2008, 27:77 http://www.jeccr.com/content/27/1/77
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In vitro cell migration assay
This migration assay was a modification of the assay
described previously [15], which measured cell migration
through an 8.0-μm pored membrane (BD Biosciences,
Bedford, MA). In the lower chamber, 600 μl of RPMI 1640
medium containing 20% FBS and 10 μg/ml of bovine
fibronectin was placed. 2 × 104 cells in 100 μl of RPMI
1640 medium supplemented with 20% FBS were placed
in the upper chamber. After 6 h-incubation, the number
of migrated cells (lower side of the membrane) was
counted as described above. Assays were done in triplicate
for each experiment, and each experiment was repeated
three times.
Reverse transcription-polymerase chain reaction (RT-
PCR)
The procedures for reverse transcription-polymerase chain
reaction (RT-PCR) were essentially as usual. The forward
and reverse primers corresponding to human IQGAP1
were 5'-ACCGTGGACCCAAAGAAC-3' (forward), 5'-
CTTCCCGTAGAACTTTTTGTTG-3' (reverse) [16]. Beta-
actin mRNA was amplified with forward (5'-
TTGCCGACAGGATGCAGAA-3') and reverse (5'-
GCCGATCCACACGGAGTACT-3') primers in a similar
fashion. All RNA was extracted by using Trizol reagent
(Invitrogen) according to the manufacture's instructions.
Total RNA was reverse transcribed in 20 μl reaction system
using Superscript First-Strand Synthesis Kit for RT-PCR
(Invitrogen) under conditions described by the supplier.
The PCR cycling program was 94°C for 5 minutes, then 30
cycles of 94°C for 30 seconds, 55°C for 60 seconds, and
72°C for 30 seconds, and a final extension at 72°C for 10
min. The RT-PCR products obtained were electrophoresed
through a 2% agarose gel with ethidium bromide.
Western blot analysis
Whole cellular protein was obtained with M-Per Mamma-
lian Protein Extraction Reagent (Pierce, Rockford, IL). The
aliquots were separated on SDS-PAGE (10%) and trans-
ferred to nitrocellulose membranes. Antigen-antibody
complexes were detected ECL blotting analysis system
(Amersham Biosicences Inc.). The IQGAP1 antibody
(H00008826-M01) was purchased from Novus Biologi-
cals. Anti-b-actin antibody was obtained from Sigma Bio-
technology. The secondary antibody was sc-2005, a goat
anti-mouse immunoglobulin G, horseradish peroxidase
(HRP) conjugate.
Statistical analysis
Statistical analyses were performed using SPSS statistical
software (SPSS Inc., Chicago, Illinois). Student's t-test was
adopted. Significance was defined as P < 0.05.
Results
IQGAP1 expression in ovarian cancer cell lines
We used RT-PCR and Western blot analysis to characterize
expression of IQGAP1 in three human ovarian cancer-
derived cell lines (SK-OV-3, HO-8910 and HO-8910PM).
IQGAP1 mRNA and protein was detectable in all these
three cell lines, with highest expression in HO-8910PM,
moderate expression in SK-OV-3 and weak expression in
HO-8910 cells (Fig. 1a and 1b).
IQGAP1 expression and invasive phenotype in ovarian 
cancer cell lines
IQGAP1 is thought to mediate tumor cell invasion and
migration in several types of cancer. To assess the role of
IQGAP1 in conferring invasive properties to cells derived
from ovarian cancer, we first determined whether expres-
sion of endogenous IQGAP1 correlated with invasive and
migratory ability by using an in vitro Matrigel assay and
cell migration assay. In contrast to SK-OV-3 and HO-8910
cells with markedly reduced endogenous IQGAP1 expres-
sion, HO-8910PM cells expressed high levels of IQGAP1
protein displayed much higher metastatic potential after
24-h incubation. The number of HO-8910PM cells that
passed through the Matrigel-coated membrane was 1.3
times and 1.6 times larger than the number of SKOV-3
and HO-8910 cells, respectively (P < 0.05) (Fig. 1c). After
6 h-incubation, HO-8910PM cells showed much stronger
migratory activities compared with SK-OV-3 and HO-
8910 cells (P < 0.05) (Fig. 1d). Thus, these findings sug-
gest that IQGAP1 expression level seemed to be closely
associated with the enhanced invasion and migration in
ovarian cancer cell lines.
Gene silencing for IQGAP1 gene
To further investigate whether IQGAP-1 can induce cancer
cell invasion and migration, we knocked down IQGAP1
using shRNA expressing plasmids controlled by U1 pro-
moter (Clone 1, 2, 3 and 4) in HO-8910PM cells and
selected by growth in the presence of puromycin. We first
examined the knock-down efficiencies of different
IQGAP1 shRNAs using Western blot analysis. HO-
8910PM-shIQGAP1 cells (Clone 1, 2, 3 and 4) showed a
significant decrease in IQGAP1 mRNA and protein expres-
sion when compared with HO-8910PM-shRNA negative
cells or un-transfected HO-8910PM cells (Fig. 2). The
above results demonstrated that the expression of
IQGAP1 could be down-regulated specifically and effec-
tively by specific IQGAP1 shRNA.
Effects of IQGAP1 specific shRNA on cell proliferation 
activity
The proliferation activity of tumor cell is important in
invasion and metastasis of tumor. We examined cell pro-
liferation activity of HO-8910PM-shIQGAP1 (clone 1),
HO-8910PM-shRNA negative cells and un-transfectedJournal of Experimental & Clinical Cancer Research 2008, 27:77 http://www.jeccr.com/content/27/1/77
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HO-8910PM cells using MTT assay. The proliferation rates
of HO-8910PM-shIQGAP1 cells were similar to HO-
8910PM-shRNA negative and un-transfected HO-
8910PM cells (Fig. 3). The results showed that knock-
down of IQGAP1 in the HO-8910PM cells by shRNA did
not change the cell proliferation activity in vitro.
Silencing of IQGAP1 inhibited ovarian cancer cell invasion 
in vitro
Invasion of basement membranes by tumor cell is
thought to be a critical event in the cascade of metastasis.
It has been shown that over-expression of IQGAP1
enhances the capacity of human breast adenocarcinoma
MCF-7 cell for transmembrane migration by up-regulat-
ing the expression active CDC42 and Rac1 [17]. To evalu-
ate whether silencing of IQGAP1 contributes to the
reduced invasive behavior of ovarian cancer cells, we
examined the invasive potential of IQGAP1 shRNA trans-
fectants using an in vitro Matrigel-coated invasion assay.
HO-8910PM-shIQGAP1 cells displayed a significantly
lower transmembrane migration activity as compared to
HO-8910PM-shRNA negative and un-transfected HO-
8910PM cells (Fig 4a). This result suggested that suppres-
sion of IQGAP1 by shRNA resulted in a significant
decrease in the invasiveness of ovarian cancer cells.
shows that IQGAP1 expression and cell invasive phenotype in ovarian cancer cell lines Figure 1
shows that IQGAP1 expression and cell invasive phenotype in ovarian cancer cell lines. (a) RT-PCR analysis for 
IQGAP1 using total RNA form HO-8910, SK-OV-3 and HO-8910PM cells.   (b) Western blot analysis for IQGAP1 in whole-
cell lysates from the indicated cell lines.   (c) High IQGAP1 expression associated with enhanced invasive potential of ovarian 
cancer cells. HO-8910, SK-OV-3 and HO-8910PM cells were seeded onto a Matrigel-coated invasion chamber and the number 
of invading cells was determined as described before.  *, P < 0.05 versus SK-OV-3 or HO-8910 cells.   (d) High IQGAP1 
expression correlated with enhanced migratory potential of ovarian cancer cells. HO-8910, SK-OV-3 and HO-8910PM cells 
were seeded onto a Boyden chamber and the number of migrating cells was determined as described before.  *, P < 0.05 ver-
sus SK-OV-3 or HO-8910 cells.   
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Suppression of IQGAP1 decreased cell mobility
Active cell motility is another rate-limiting step of tumor
cell invasion. To explore whether shRNA-induced gene
silencing of IQGAP1 affect the motility properties of HO-
8910PM cells, we also compared the cell motility using an
in vitro cell migration assay. After 6 h-incubation, HO-
8910PM-shIQGAP1 cells showed a significantly lower cell
invasion activity as compared to HO-8910PM-shRNA
negative and un-transfected HO-8910PM cells (Fig. 4b),
suggesting that suppression of IQGAP1 decreases cell
motility, therefore, supporting a important role for
IQGAP1 in the metastasis of ovarian cancer cells [10].
Discussion
IQGAP1 is a scaffolding protein that binds to a diverse
array of signaling and structural molecules. Accumulated
evidences have demonstrated that IQGAP1 may be critical
for conferring invasive potential in various human cancers
[8,17]. We have reported that of IQGAP1 was a novel
marker of poor outcome in patients with ovarian carcino-
mas [10]. In the present study, we have shown that ovar-
ian cancer cell line HO-8910PM, which expresses high
levels of endogenous IQGAP1, showed extremely high
invasive abilities through the reconstituted basement
membrane Matrigel. Furthermore, gene silencing for
IQGAP1 in HO-8910PM cells resulted in reduced cell
migration. This was consistent with previous findings that
down-regulation of IQGAP1 by IQGAP1-specific siRNAs
effectively blocks HA-CD44-stimulated SK-OV-3 ovarian
tumor cell migration [18]. More importantly, we first
demonstrated that knockdown of IQGAP1 also led to
attenuated Matrigel invasiveness, suggesting that thera-
indicates that IQGAP1 mRNA and protein levels in HO-8910PM-shIQGAP1, HO-8910PM-shRNA negative and un-transfected  HO-8910PM cells were determined by RT-PCR and Western blot analysis, respectively.  Figure 2
indicates that IQGAP1 mRNA and protein levels in HO-8910PM-shIQGAP1, HO-8910PM-shRNA negative and un-transfected 
HO-8910PM cells were determined by RT-PCR and Western blot analysis, respectively. 
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pies targeting IQGAP1 activity may prove efficacious for
treating ovarian cancer metastasis. Moreover, accumulat-
ing evidences have shownthat non-viral vectors will be an
attractive alternative to viral vectors due to their safety,
versatility and ease of preparation and scale-up [19]. Intra-
venous delivery of liposome-mediated nonviral DNA has
also been proved to be less toxic than intraperitoneal
delivery in mice [20]. Therefore, we will further investigate
the effects of IQGAP1-shRNA plasmids by intravenous
administration on ovarian cancer metastasis in animal
models.
In addition, recent study demonstrated that IQGAP1 stim-
ulated proliferation of human breast epithelial cells [21].
However, our result indicated that IQGAP1-specific
shRNA did not influence cell proliferation in HO-
8910PM cells, suggesting that IQGAP1 may induce cell
proliferation rate in a cell type-dependent mechanism.
Collectively, these findings suggest that IQGAP1 plays an
important role in the invasion and metastasis of ovarian
cancer cells.
The acquisition of invasive potential by tumor cells is
undoubtedly a complex process. Degradation of extracel-
lular matrix and basement membrane, promotion of cell
motility and enhanced tumor cell proliferation are
thought to be essential steps. It has been shown that
IQGAP1 captures and stabilizes microtubules through the
microtubule-binding protein CLIP-170 near the cell cor-
tex, leading to establishment of polarized cell morphol-
ogy and directional cell migration [5]. Moreover, IQGAP1
regulates Salmonella invasion through interactions with
actin, Rac1, and Cdc42 [9]. To gain full understanding of
molecular mechanisms by which IQGAP1 regulates cell
invasion, DNA microarray analysis was further needed to
identify key genes involved in IQGAP1-dependent ovar-
ian cancer cell invasiveness.
Inhibiting the expression of pathogenic genes by shRNA-
induced RNA interference has proved to be a successful
approach to reducing the malignance of different tumor
cells [22]. In the present study, we selectively silenced
IQGAP1 expression in human ovarian cancer cells by
exploiting RNAi technology. Furthermore, selective inhi-
shows that proliferation of HO-8910PM cells stably expression shRNA Figure 3
shows that proliferation of HO-8910PM cells stably expression shRNA. Proliferation of HO-8910PM-shIQGAP1 
(clone 1), HO-8910PM-shRNA negative and un-transfected HO-8910PM cells were analyzed by MTT assay as described ear-
lier.   
72 h
0
0.1
0.2
0.3
0.4
0.5
A
b
s
o
r
b
a
n
c
e
Fig. 3
24 h 48 h
HO-8910PM-shIQGAP1
HO-8910PM-shRNA negative
HO-8910PM
(
4
5
5
/
6
5
5
)
96 hJournal of Experimental & Clinical Cancer Research 2008, 27:77 http://www.jeccr.com/content/27/1/77
Page 7 of 8
(page number not for citation purposes)
indicates that silencing of IQGAP1 inhibited ovarian cancer cell invasion and migration in vitro Figure 4
indicates that silencing of IQGAP1 inhibited ovarian cancer cell invasion and migration in vitro. (a) Suppression 
of IQGAP1 hampered transmembrane migration ability of HO-8910PM cells. HO-8910PM-shIQGAP1, HO-8910PM-shRNA 
negative and un-transfected HO-8910PM cells were seeded onto a Matrigel-coated invasion chamber and the number of invad-
ing cells was determined as described before.  *, P < 0.05 versus HO-8910PM-shRNA negative or un-transfected HO-8910PM 
cells.     (b) Suppression of IQGAP1 decreased migration of HO-8910PM cells. HO-8910PM-shIQGAP1, HO-8910PM-shRNA 
negative and un-transfected HO-8910PM cells were seeded onto a Boyden chamber and the number of migrating cells was 
determined as described before.  *, P < 0.05 versus HO-8910PM-shRNA negative or un-transfected HO-8910PM cells.  
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bition of IQGAP1 significantly reduced metastatic poten-
tial of IQGAP1-expressing human ovarian cancer cell in
vitro by affecting multiple aspects of tumor invasion, rais-
ing the possibility that RNA interference against IQGAP1
is an effective strategy for anti-metastasis of IQGAP1
expressing ovarian cancer cells.
Ovarian cancer is the fifth most common cancer, and it is
the leading cause of death from all types of gynecologic
cancer. It is urgent to develop new therapeutic strategies
for ovarian cancers. In this report, the knockdown of
IQGAP1 expression by RNAi can successfully reverse the
malignant behaviors of ovarian cancer cells, implicating
that IQGAP1 may be a new candidate of drug target for
treatment of ovarian cancers.
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